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Protein kinases are a large group of enzymes that play a major role in regulating 
signalling processes, DNA replication and transcription, cell differentiation and 
carbohydrate and lipid metabolism. JAKs are members of the Janus kinase family 
belonging to the group of non-receptor tyrosine kinases. The research group, led by Olli 
Silvennoinen, investigates the JAK-STAT signaling pathway, which regulates gene 
expression by mediating extracellular signals to nucleus via cell-surface receptors. 
Several cytokines and hormones activate the JAK-STAT pathway and its dysfunction 
affect the cell’s ability to differentiate, proliferate, develop and survive. The objective of 
this study was to investigate the solubility, structure and function of kinase domain 
(JH1) and pseudokinase domain (JH2) of JAK2 protein. The purpose was to generate a 
kinase inactivating mutation K581A in the pseudokinase domain and produce 
recombinant JAK2 protein in Baculosystem.  

JAK2 is an essential protein in erythropoiesis and myeloid differentiation. Mutations in 
JAK2 affect its structure and function in the JAK-STAT pathway, leading to 
myeloproliferative diseases. The production of inactive and soluble proteins has shown 
to be a difficult task. In this study, bac-to-bac expression system was used to produce 
desired recombinant proteins. Two different sizes of mutated DNA -constructs were 
transformed into competent DH10Bac cells for generating recombinant bacmid DNA, 
which was isolated and transfected into Sf9 cells. Fresh insect cells were infected with 
the baculovirus particles harvested from media. Western blot results indicate that the 
insect cells were able to express the mutant JAK2 -protein but not in soluble form.  
 
The aim of the thesis was to produce stable and soluble protein which can be used in 
structural studies of two-domain JAK2The mutations, K581A and D976N together 
could have interfered with the stability of the JAK2 and induce the protein insoluble. 
The catalytical activity of JAK2 is regulated by tyrosine residue phosphorylation in the 
kinase domain and only the crystal structures of pseudokinase (JH2) and kinase (JH1) 
domain have been resolved. In the future, more recombinant protein production is 
required for X-ray crystallography studies which will give more information on the 
three-dimensional structure and catalytic activity of JAK2 and allow the development of 
new therapeutic drugs for a trial. The constructs can be used again to produce high 
amounts of recombinant proteins, which can be purified for structural studies. 
 
  
 
 
Key words: Recombinant protein, JAK2, K581A, phosphorylation, molecular cloning, 
Baculovirus system

TIIVISTELMÄ
Tampereen ammattikorkeakoulu
Laboratorioalan koulutusohjelma 
HOVINEN, EMILIA: 
K581A -mutaation luominen ja rekombinantin JAK2-proteiinin tuotto 
Opinnäytetyö, 50 sivua
Joulukuu 2012 
 
 
JAK-kinaasit ovat entsyymejä, joilla on tärkeä rooli solusignaloinnin säätelyssä, DNA:n 
kahdentumisessa ja transkriptiossa sekä solujen kyvyssä lisääntyä ja erilaistua. Janus 
kinaasit ovat sytokiinireseptoreihin sitoutuvia tyrosiinikinaaseja, jotka välittävät 
sytokiinin signaalin solun sisään autofosforylaation sekä solunsisäisten signalointi-
reittien aktivoitumisen kautta. Professori Olli Silvennoisen tutkimusryhmä selvittää 
JAK-kinaasien säätelymekanismeja immuunivastetta heikentävissä sairauksissa. 
Sytokiinireseptorien avulla JAK-STAT signaaliketju säätelee geenien ilmentymistä 
välittämällä solun ulkopuolisia signaaleja tumaan. Useat sytokiinit ja hormonit 
aktivoivat JAK-STAT signaaliketjua. Häiriöt signaaliketjun toiminnassa vaikuttavat 
solun kykyyn lisääntyä, erilaistua, kehittyä ja selviytyä.  

JAK2-proteiinilla on tärkeä tehtävä erytropoieesissa ja myeloidisten solulinjojen 
erilaistumisessa. JAK2:ssa esiintyvien mutaatioiden on todettu aiheuttavan raken-
teellisia ja toiminnallisia muutoksia proteiinissa sekä johtavan erilaisiin myelo-
proliferatiivisiin sairauksiin. JAK2:n biologista ja rakenteellista tutkimusta on 
hidastanut sen epästabiili rakenne, minkä vuoksi proteiinista haluttiin mutaatioiden 
avulla inaktiivinen. Opinnäytetyön tarkoituksena oli luoda JAK2:n pseudokinaasiosaan 
eli JH2-domeeniin inaktivoiva K581A-mutaatio ja tuottaa rekombinanttia proteiinia 
bakulovirussysteemissä. Työn tavoitteena oli analysoida tuotettujen JAK2-domeenien 
liukoisuutta sekä tutkia niiden kolmiulotteista rakennetta ja toimintaa. Proteiinia 
tuotettiin Bac-to-Bac® Baculovirus Expression Systemtuottosysteemillä. Kompetentit 
E. coli-solut transformoitiin mutatoidulla plasmidilla rekombinantin bakmidin 
aikaansaamiseksi, minkä jälkeen bakmidi-DNA eristettiin.  Sf9-hyönteissolulinja trans-
fektoitiin eristetyllä ja puhdistetulla bakmidi-DNA:lla, ja solut alkoivat tuottaa haluttua 
rekombinanttiproteiinia.
 
Hyönteissoluissa tuotetut proteiinit analysoitiin Western blot -menetelmällä. Solut 
kykenivät ilmentämään haluttua proteiinia, mutta molemmat JAK2-konstruktit osoit-
tautuivat liukenemattomiksi. Liukoisten ja inaktiivisten proteiiniosien tuottaminen 
laboratoriossa on osoittautunut haastavaksi. Ilmeisesti K581A- ja D976N-mutaatioiden 
samanaikainen läsnäolo häiritsi tutkittavan proteiinin stabiilisuutta ja aiheutti sen 
liukenemattomuuden. Mutatoituja konstrukteja voidaan jatkossa tuottaa uudelleen 
esimerkiksi jollakin toisella tuottosysteemillä, minkä jälkeen proteiinia voidaan 
puhdistaa rakenteellista tutkimusta varten. 
 
 
Avainsanat: rekombinanttiproteiini, JAK2, K581A, fosforylaatio, DNA-
yhdistelmätekniikka, bakulovirussysteemi
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AB Antibody 
AcNPV Autographa californica nucleopolyhedrosis virus 
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ALL Acute lymphoblastic leukemia 
AML Acute myeloid leukemia 
Amp
r
 Ampicillin resistence selection gene) 
Asp Aspartic acid 
Asn Asparagine 
ATP Adenosine triphosphate  
BEVS Baculovirus Expression Vector System 
BSA Bovine serum albumin 
C Carboxyl 
D976N mutation in JH1-JH2 domains 
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D-P-G  Aspartic acid-Proline-Glycine 
DH10Bac Supercompetent cell 
DNA Deoxyribonucleic acid 
Dpn-I Restriction endonuclease  
dNTP deoxynucleotide triphosphate 
dsDNA double stranded DNA 
EDTA  EthyleneDiamineTetraAcetic acid 
ET Essential thrombocythemia (disorder in MPN) 
EtBr Ethidium bromide 
FBS Fetal bovine serum 
FERM Domain containing kinase domains JH4-JH7 
Gen
r
 Gentamycin (a selection gene) 
GTP Guanosine triphosphate 
GV Granulovirus genus 
H-R-D Histidine-Arginine-Aspartic acid 
IBT Institute of Biomedical Technology 
IgG Immunoglobulin G, antibody isotype 
IgG-HRP IgG conjugated to Horseradish peroxidase 
IPTG Isopropyl beta-D-thiogalactopyranoside 
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JAK1 Janus Kinase 1 
JAK2 Janus Kinase 2 
JAK3 Janus Kinase 3 
JH1-JH7 JAK homology domains 
JH1 Kinase domain (homology domain) 
JH2 Pseudokinase domain (homology domain) 
kDa Kilodalton 
K581A Kinase-inactivating point mutation in domain JH2 
K882 Mutation in domain JH2 
LB Luria broth medium 
MCS Multiple cloning site 
mini-attTn7 Mini Tn7 
MPN Myeloproliferative neoplasms 
N Amino 
NPV Nucleopolyhedrovirus  
NRTK Non-receptor tyrosine kinase 
NZY Reagent containing NZ Amine-A (casein hydrolysate) 
ORI Origin for DNA replication 
P0 Passage zero virus 
P1 Passage one viruses 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
pFastBac1™  Donor vector 
PK Protein kinase 
PMF Primary myelofibrosis (disorder in MPN) 
PMSF Phenylmethylsulphonyl fluoride 
PTK Protein tyrosine kinase 
pUC19 Plasmid vector  
PV Polycythemia vera (disorder in MPN) 
RNAse Ribonuclease 
RTK Receptor tyrosine kinase 
S.O.C Nutrient media 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Ser523 Amino acid serine, residue 523 
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Sf9 Spodoptera frugiperda, insect 
SH2 Src homology-2  
Sol Solution 
ssDNA single stranded DNA 
STAT Signal Tranducer and Activators of Transcription 
TAE Buffer containing a mixture of Tris base, acetic acid and 
EDTA 
Taq Thermostale DNA polymerase named after bacterium 
Thermus aquaticus 
TBS Tris-buffered saline 
TE Tris-EDTA buffer 
Tn7L, Tn7R Left and right ends of transposon Tn7 
Tris Tris (hydroxymethyl) aminomethane 
TYK2 Tyrosine kinase 2 
Tyr570 Amino acid tyrosine, residue 570 
V671F Mutation in JAK2 
V-A-I-K Valine-Alanine-Isoleusine-Lysine 
Y1007, Y1008 Tyrosine residues 
X-Gal 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
XL1-Blue Supercompetent cell  
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 INTRODUCTION 1
 
 
This Bachelor’s thesis was carried out in the research group of Professor Olli 
Silvennoinen at the Institute of Biomedical Technology (IBT), University of Tampere. 
The thesis was supervised by Daniela Ungureanu, PhD. Olli Silvennoinen’s group is 
focused on cytokine signalling research, trying to understand the mechanism of cellular 
and molecular regulation of the JAK-STAT pathway.

JAK2 is a key protein involved in erythropoiesis and myeloid differentiation. 
Expressing and purifying JAKs has been difficult and mutations in JAK2 that are gain-
of-function mutations, lead to many forms of myeloproliferative disorders. One of the 
most known is V617F mutation that induces polycythemia vera. Therefore, 
understanding the mechanism of JAK2 regulation is very important, offering the right 
platform for developing disease treatments. 

The objective of this thesis is to analyze the solubility and biological function of 
recombinant JAK2 protein produced in Baculo system. The purpose is to mutate JH1-
JH2 domains of JAK2 protein and express the mutated recombinant protein in insect 
cell line.

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 THEORETICAL BACKGROUND 2
 
 
2.1. Protein kinases 
 
Protein kinases (PKs) are a large group of enzymes which catalyze transfer of a 
phosphate group, usually from ATP to the hydroxyl group of tyrosine, threonine or 
serine residue of their substrates (Choreschi K. et al. 2009) Vertebrate genome consist s 
of approximately 2000 different protein kinase enzymes. Protein kinases play an 
inevitable role in regulating signalling processes, DNA replication and transcription, 
cell differentiation and carbohydrate and lipid metabolism. Protein kinases are divided 
in two major classes based on which substrate they phosphorylate (Figure 1, p. 11). 
Protein kinases phosphorylating serine or threonine residues are called serine protein 
kinases (PSKs) and protein kinases phosphorylating tyrosine residues form a group of 
tyrosine protein kinases (PTKs) In addition to these two classes, a smaller group called 
dual-specific proteins kinases are able to phosphorylate serine and threonine residues of 
their substrates(Adams J. A. 2001)

During the recent years especially the conserved kinase domain has been intensively 
studied for its nature to stay as conserved domain through the evolution. Despite the fact 
that protein kinases have structural and regulatory differences, they all contain a highly 
conserved kinase domain which conveys the phosphotransfer reaction (Engh R.A. & 
Bossemyer D., 2001). All kinases have a catalytic domain or a kinase domain which is 
approximately 300 amino acids long. There are 518 kinases in human genome, 48 
kinases which contain a pseudokinase and only 4 kinases containing both a 
pseudokinase and a tyrosine kinase domain. (Haan C. et al., 2010)
 
 
2.1.1 Protein tyrosine kinases 
 
Protein tyrosine kinases (PTKs) are enzymes that catalyze the transfer of the terminal 
phosphate of ATP to a specific tyrosine residue in a protein. Protein tyrosine kinases 
form two subfamilies; receptor tyrosine kinases (RTKs) and non-receptor tyrosine 
kinases (NRTKs) RTKs consist of an intracellular tyrosine domain, a transmembrane 
domain and an extracellular ligand-binding domain. RTKs are transmembrane 
11 
glycoproteins that become activated as a result of the binding of their ligands. The 
binding ligand can for instance be a cytokine or a hormone. NRTKs are soluble, 
cytoplasmic kinases. They do not contain any transmembrane domains to act as 
receptors, but they interact via SH2 or SH3 domains. The JAKs belong to NRTKs and 
are non-covalently associated with the cytoplasmic domain of their corresponding 
receptor. (Hubbard S.R. et al., 2000)


FIGURE 1. A Simple depiction of the protein kinases(Derived; Adams J. A. 2001)
 
 
2.2. Protein phosphorylation 
 
Amino acids serine, threonine and tyrosine can form phosphate esters, where the 
phosphate binds covalently to a hydroxyl group of the residues. Phosphorylation (Figure 
2, p.12) affects the structure and catalytic activity of an enzyme and binding of the 
substrate. When a phosphate is removed by protein phosphatase, dephosphorylation 
occurs and on the contrary when a phosphate is attached by protein kinases, 
phosphorylation takes place. The energy for phosphorylation is usually obtained from 
ATP which donates the phosphate and forms ADP. (Campbell M.K. & Farrel S.O., 
2008)

12 

    
FIGURE 2. Amino acid tyrosine becomes phosphorylated when a phosphate binds to a hydroxyl 
group on the tyrosine residue (Modified; Campbell M.K. & Farrel S.O., 2008)


Phosphorylation plays an essential role in transferring signals from the outside to the 
inside of a cell and regulates various cellular processes such as growth, motility, 
metabolism, proliferation and differentiation (Walker J.M., 2009)The phosphorylation 
of the protein kinases requires a divalent metal ion (Mg
2+
) which helps the binding of 
ATP (Adams, J. A. 2001). The metal ion acts as one of the enzyme substrates and binds 
either with ATP or GTP and chelates the β- and γ-phosphoryl groups (Matte A. et al., 
1998)
 
 
2.3. The JAK-STAT pathway 
 
The JAK-STAT signaling pathway (Figure 3, p.14) regulates gene expression by 
conveying extracellular signals to nucleus via cell-surface receptors. STATs (signal 
transducers and activators of transcription) are latent gene regulatory proteins which are 
normally inactive and located in the cytosol. (Alberts, B., et al., 2008) Seven 
mammalian STATs are known (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b 
and STAT6) (Paukku K. & Silvennoinen O, 2004). STATs are 700-900 amino acids 
long and their structure contains a SH-domain which has two functions (Kisseleva T et 
al., 2001). First, to mediate the STAT protein’s binding on the cytokine receptor and 
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secondly, to mediate the STAT protein’s binding to another STAT molecule (Alberts, 
B., et al., 2008) The cytokine receptors consist of an extracellular domain, a single 
transmembrane domain and intracellular domains which mediate the signaling function 
(Saharinen P. 2002)

In the JAK-STAT pathway, a ligand (cytokine, growth hormone, interleukin or 
interferon) binds to its receptor leading the receptors to oligomerize. This induces the 
JAKs trans-phosphorylation on the tyrosine residues. Activated JAKs phosphorylate the 
cytokine receptors and form specific phosphotyrosine docking sites for STATs. The 
JAKs phosphorylate the STATs and the cytokine receptors activate the STATs which 
dissociate from the cytokine receptors and form a homodimer or heterodimer. 
(Kisseleva K.,2001) STAT dimer translocates to the nucleus and with the help of other 
gene regulatory proteins start to stimulate the target genes (Imada K. & Leonard W.J., 
2000).Several cytokines and hormones activate the JAK-STAT pathway and its 
dysfunction affects the cell’s ability to differentiate, proliferate, develop and survive 
(Paukku K. & Silvennoinen O., 2004). 
14 


FIGURE 3 The JAK-STAT signalling pathway. A cytokine binds to its receptors and induces 
the receptors to converge each other which trigger the JAKs to trans-phosphorylate one 
another. As a result the activated JAKs phosphorylate the cytokine receptors which recruit the 
STATs. Phosphorylated STATs migrate to the nucleus and with the help of other gene regulatory 
proteins bind to a specific DNA sequences and start to stimulate the transcription of target 
genes (Modified; Alberts B. et al., 2007)

 
2.4. The family of Janus kinases 
 
The family of Janus kinases (JAKs) consists of four mammalian members; JAK1, 
JAK2, JAK3 and TYK2. JAKs have also been found in birds, fish and insects. Human 
JAK1 gene is located on chromosome 1p31.3, the JAK2 gene on chromosome 9p24, the 
JAK3 gene on chromosome 19p13.1 and TYK2 gene on chromosome 
19p13.2(Firmbach-Kraft I. et al. 1990)

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JAK structure comprises seven conserved homology domains, JH1-JH7 (Figure 4). The 
major feature of the JAK kinases structure is that they consist of a tyrosine kinase 
domain (JH1) and pseudokinase domain (JH2) which comprise approximately half of 
the entire JAK molecule and are located at C-terminal side of the JAKFERM domain 
forms the other half of JAK at the N-terminal side. SH2-like domain is located in the 
middle between pseudokinase domain and FERM domain. (Hubbard et al. 2000)

  JH5

N C      C



 

The JAKs kinases are relatively large molecules and their molecular weight ranges 
between 120-140 kDa (Kawamura et al., 1994)The FERM domain (30 kDa) binds to 
JAK’s receptor and the SH2-like domain structurally supports and stabilizes the FERM 
domain by binding phosphotyrosine residues in the next protein in the signaling 
pathway (Leonard & O’Shea, 1998). The SH-like domain does not act as a typical 
phosphotyrosine-binding domain and its exact role is still unknown (Bandaranayake et 
al., 2012)

The tyrosine kinase domain (JH1) is approximately 300 amino acids long domain and 
has a nature of a typical eukaryotic tyrosine kinase domain. It has an important role as a 
catalytically active domain. (Briscoe et al., 1996, Gurniak & Berg, 1996, Sanz et al., 
2011) JH1 domain contains the active site (A-loop) and binds the ATP during the 
phosphorylation. The pseudokinase domain (JH2) is conserved in all JAK 
kinases,referring that the JH2 domain may have a major role for the function of JAK 
protein (Wilks A.F et al., 1991). The JH2 domain was assumed to be catalytically 
inactive domain but was discovered to be an active domainThe JH2 domain plays an 
essential role in regulating the activation of the whole JAK protein. (Sanz et al., 2011).
 
 JH7 JH6 JH1 JH2  JH4 JH3 
FERM domain SH2-like 
domain 
Pseudokinase 
domain 
FIGURE 4 Schematic domain structure of JAK kinases (Modified; Ungureanu, D. 2005) 
Tyrosine kinase 
domain 
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2.4.1 The structure of JH1-JH2 domains of JAK2 

The whole JAK2 protein is composed of 1132 amino acids (European Bioinformatics 
Institute, 2012)Only the crystal structures of JH1 and JH2 domains of JAK2 have been 
resolved. Despite few differences, they both share a structure of a typical folding of a 
eukaryotic protein kinase.(Bandaranayake et al., 2012) The phosphotransfer reaction 
occurs in the active site (A-site) that is located between the amino-terminal lobe (N-
lobe) and carboxyl-terminal lobe (C-lobe). These two lobes are further divided into 
twelve subdomains and between those are the activation loop and the catalytic loop. 
The N-lobe consists of five β-strands and single α-helix called α-C. The C-lobe is 
mainly α-helical. (Hanks S.K. & Hunter T., 1995) The first subdomain (I) including 
β1β2 strands in the N-lobe contains an amino acid sequence with several conserved 
glycines (Gly) (Saharinen P. et al., 2000) This motif is often called a nucleotide 
binding pocket where the ATP binds (Huse M. & Kuriyan J., 2002). The activation loop 
of JH2 (Figure 5, p.17) domain is shorter than in JH1 domain (Bandaranayake et al., 
2012).

The second subdomain (II) which is a β3-strand in the N-lobe contains also a conserved 
motif, V-A-I-K (Valine-Alanine-Isoleusine-Lysine). In the JH2 domain of JAK2, the 
conserved glutamic acid is changed to alanine. The subdomain VIb is called the 
catalytic loop (β6-7 strands) containing aspartic acid (Asp), H-R-D (Histidine-Arginine-
Aspartic acid) role is to receive a proton for the phosphotransfer reaction. In the JH2 
domain the aspartic acid is replaced with asparagine (Asn). β8-9 strands in subdomain 
VII contain a motif DFG (Aspartic acid-Phenylalanine-Glycine) which is located at 
the start of the activation loop and is able to align easily with other tyrosine 
kinases(Huse and Kuriyan, 2002) The similar motif in the JH2 domain is D-P-G 
(Aspartic acid-Proline-Glycine) (Bandaranayake et al., 2012).


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

FIGURE 5. Crystal structure of JH2 domain of JAK2 protein. N- and -C terminals are 
described with light grey color, yellow color presents the N-lobe except nucleotide-binding is 
colored blue and αC yellow. The activation loop has a green color and the Mg2+ between the 
green and orange colors is labeled with purple. Orange color presents the catalytic loop. ATP 
is shown in the middle and is colored with red, blue and black. The α-helices and β-strands are 
also marked in the figure. (Bandaranayake et al., 2012)

 

2.4.2 Mutations in JAK2 

There have been several structural studies performed to investigate the function of 
JAKs, including point mutations, partial deletions or deletion of a whole domain. It has 
been indicated that JAKs lacking the JH3-JH7 domains, are not able to bind their 
receptors. While a mutant TYK2 with erased JH2 domain inhibits the catalytic activity 
and function of the protein, in contrast a similar JAK2 is capable to function and 
actually has shown to increase its catalytic activity. (Lindauer K. et al., 2001)

A number of studies indicate that mutations in human JAK genes cause 
myeloproliferative neoplasms (MPNs) affecting myeloid lineages (Bandaranayake et 
al., 2012). MPNs include three main disorders, polycythemia vera (PV), essential 
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thrombocythemia (ET) and primary myelofibrosis (PMF) which cannot be cured for the 
present (MPN Research Foundation, 2012). 
Also mutations in JH2 domain of JAK1, JAK2 and JAK3 are proved to be associated 
with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) 
(Bandaranayake et al., 2012). 
 
Many mutations in JH2 of JAK2 have been analyzed and more than thirty mutations are 
proved to be linked to hematological diseases (Haan et al., 2010). Deletion of JH2 
domain induces functional changes in JAKs (Saharinen P., 2002). Proposed role for 
JH2 domain is to regulate the kinase domain activity in absence of cytokine signalling. 
It has been suggested that mutations in JH2 domain disrupt the inhibitory interaction 
between JH1-JH2 domains of JAK2 or may even induce gain-of-function constitutive 
activity. Activating mutations such as V617F may lead to myeloproliferative diseases. 
(Boudeau J. et al., 2006)

Though the structure of JH2 domain shares similarity to JH1 domain, mutations in JH2 
domain induce the lack of kinase-activity (Ungureanu D. et al., 2011). For example, 
K882 mutation in the JH2 domain has shown to generate deficient kinases and to 
inactivate the JAK2 (Briscoe J., 1996). K581A is a kinase-inactivating point mutation 
and inhibits binding of ATP to the active site of the JH2 domainIn the mutation, a 
large and positively charged lysine is converted to a small uncharged alanine. K581A 
mutation is located in the (β-3 strand) in the N-lobe of the JH2 domain (Figure 6, p.19). 
K581A mutation participates the binding of ATP by coordinating the α- and β-
phosphates. This is assumed to inhibit the efficient binding of ATP into the nucleotide 
binding pocket. (Ungureanu D. et al., 2011) 
19 


FIGURE 6. ATP binding in JH2 domain of JAK2. Orange color describes the catalytic loop, red 
color is marked for oxygen, blue for nitrogen and black for phosphorus. Mg
2+
 is colored purple. 
The residue K581 is also shown in the figure. (Bandaranayake et al., 2012)
 
 
2.4.3 Regulation of JAK2 protein 
 
Several tyrosines are phosphorylated as a result of the activation of JAK2. There are 
two tyrosine residues, Y1007 and Y1008 which become phosphorylated in the A-loop 
(Bandaranayake et al., 2012). The precise mechanism remains unknown, but it has been 
proposed that when Y1007/Y1008 phosphorylate, it leads to a conformational change 
and provides space for JH1 activation. This action induces ATP to bind into the 
nucleotide binding pocket(Ungureanu D. et al., 2002)

The pseudokinase domain, JH2, phosphorylates two negatively regulatory sites in 
JAK2, Ser523 (in cis) and Tyr570 (in trans) which conserve low basal activity of JAK2 
and do not occur in other JAKs. This leads to an assumption that JAK2 is the only JAK 
which has an additional negative regulatory mechanism. (Ungureanu D., et al., 2011)
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2.5. Production of recombinant proteins 
Recombinant protein is a protein whose amino acid sequence is encoded by a cloned 
gene (Glick B.R. et al., 2010) Heterologous protein production is discussed when the 
cells express recombinant proteins which the cells do not naturally produce (Walsh G., 
2002). These proteins are produced artificially by ligating the protein coding gene of 
interest into an appropriate vector using recombinant DNA techniques. Recombinant 
proteins are widely used in medicaments, vaccines or as biotechnological enzymes in 
industrial processes. Recombinant proteins can also be used to analyze their biological 
activity, to study their three dimensional structure and interactions with other molecules, 
to develop site-specific drugs or to produce therapeutic proteins. (Florian M.W. 2004)

After ligating the protein coding gene and the vector together, the recombinant DNA is 
introduced to a host cellBacteria, yeast and mammalian cells such as an insect cell can 
act as a host organismCells that are able to take DNA in from outside environment are 
called competent cellsThe process of introducing the desired DNA sequence into the 
host cell is transformation when the host organism is a bacterial or a yeast, and 
transfection when the host organism is a mammalian cell. After transformation or 
transfection of the host organism, the cell starts to produce recombinant 
proteins(Baltimore D. et al., 1999)

 
2.6. Molecular cloning 
 
Molecular cloning (Figure 8, p. 22) is a process where genetic information is transferred 
from one organism to another.  A specific DNA fragment is first isolated and then 
inserted to a plasmid vector. To obtain the gene of interest out from the cell, the cell 
membrane and lipid bilayer of nucleus need to be broken downThe cells can be lysed 
with mechanical, chemical, physical or enzymatic way. The isolated DNA is purified 
and fragmented using restriction endonucleases which cut the DNA at a specific 
sequence of nucleotides. These restriction enzymes such as EcoRIare naturally found 
in bacteria where they use the enzymes as a defense of a viral infection. The restriction 
enzymes are able to cut the DNA into so called “blunt ends” or “sticky ends” which is 
more often used in molecular cloning (Figure 7). The sticky ends leave longer 
overhangs which are ssDNA left over after the cleaving. (Glick B.R., 2010) 
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

FIGURE 7DsDNA sequence of the desired gene is cut with restriction endonuclease(s) as a 
result of blunt ends or sticky ends. The restriction site is colored green.

The vector used in the cloning need to be cut with the same restriction enzyme than the 
desired DNA fragment to achieve the exact recombination of the base pairs. Many small 
and identical DNA fragments are produced and circular plasmid DNAs are linearized 
into smaller fragments by the treatment of restriction endonucleaseThese DNA 
fragments are joined together with assistance of an enzyme ligase. The recombinant 
molecule is introduced to a host organism that will express the recombinant proteins. 
There are few types of vectors which can be used in molecular cloning. One of them is 
bacmid, a baculovirus shuttle vector that can replicate in both, E.coli and insect cells. 
(Glick B.R. et al., 2010)


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
FIGURE 8. Molecular cloning procedure The target gene and the vector are cleaved with the 
same restriction endonuclease. The fragments are combined and introduced to a host cell which 
will produce recombinant proteins from the cloned gene. (Modified; Glick B.R. et al., 2010) 
 
 
2.6.1 Plasmid vectors and blue-white selection 
 
Plasmids are widely used as cloning vectors whose gene regulation areas enable the 
gene expression and efficient protein production in selected hosts. (Garret R.H. & 
Grisham C.M., 2005) Plasmid is a small, circular, extrachromosomal dsDNA and has an 
ability to self-replicate. Plasmids occur naturally in bacteria, yeast and some higher 
eukaryotic cells. Recombinant DNA technology utilizes plasmids which replicate in 
E.coli. (Baltimore D. et al., 1999)

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Three major features are required for plasmid to function as a cloning vector; a 
replicator, an origin of replication (ori), a selectable marker which is usually an 
antibiotic resistance gene and a cloning site. The selectable marker helps to select the 
cells containing recombinant plasmid, and separate them from the cloning vector which 
will grow in the presence of the antibiotic. The desired gene is inserted into the cloning 
site. (Garret R.H. & Grisham C.M., 2005)

Identification of the E.coli colonies containing the recombinant plasmid is performed 
with blue-white selection. The transformed competent cells are incubated in medium in 
the presence of X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside), IPTG 
(isopropyl beta-D-thiogalactopyranoside) and ampicillin A plasmid vector (pUC19) 
contains a gene called lacZ that encodes the production of β-galactosidase. The plasmid 
also contains a resistance gene for ampicillin (Amp
r
), a lacI gene that produces a 
repressor protein regulating the expression of the lacZ gene, a multiple cloning site 
(MCS) and an origin for DNA replication (ORI)(Glick B.R. et al., 2010)

When the cells carrying the vector are grown in the medium described earlier, the 
protein product of lacI gene cannot bind to the promoter-operator region of lacZ gene 
(Glick B.R. et al., 2010). Promoter is a short DNA sequence which enables the RNA-
polymerase to attach the DNA. Promoter is located close to the gene and determines the 
site of transcription initiation for an RNA polymerase. (Baltimore D. et al., 1999) The 
lack of the repressor binding induces the lacZ gene to become transcribed and 
translated. The cell is now able to produce β-galactosidase which appears with blue 
colonies on the plate. The blue color is a result of reaction where the X-Gal is 
hydrolyzed by β-galactosidase.  Nontransformed cells cannot grow at all in the presence 
of ampicillin. The recombinant plasmid containing DNA from other source is inserted 
into the MCS region, leading to lacZ gene to be disrupted. Since the recombinant 
plasmid is not able to produceβ-galactosidase, it appears as white colonies. Positive 
colonies can be selected from the plate, grown afresh and used for further analysis. 
(Glick B.R. et al., 2010)


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2.6.2 Site-directed mutagenesis 
 
Mutagenesis is a process where the nucleotides of DNA are changed or deleted. There 
are several different methods to generate mutations into the DNA sequence. In random 
mutagenesis a variety amount of unspecific mutations are generated into different sites 
of the DNA sequence. (Glick B.R. et al., 2010) In contrast, oligonucleotide-directed 
(site-directed mutagenesis) can be performed in a bacteriophage M13 or in a plasmid 
producing specific point mutations. In this type of mutations the exact mutated 
nucleotide and the site of mutation need to be known beforehand (Sawano A. & 
Miyawaki A. 2000) A commercial test kit called QuikChange® site-directed 
mutagenesis (Stratagene) can be used for oligonucleotide-directed mutagenesis. 

QuikChange® site-directed mutagenesis test kit can be used to generate point 
mutations, switch amino acids and erase or insert single or multiple amino acids and 
does not require specialized vectors, unique restriction sites or multiple transformations. 
The procedure requires a supercoiled dsDNA vector with an insert of interest and two 
synthetic oligonucleotide primers which contain the desired mutation. (Stratagene, 
2005)

First, the plasmid is denatured, the reverse and forward primers are annealed. The 
primers are extended by the presence of PfuTurbo DNA polymerase and incorporation 
of the primers generates a mutated plasmid containing staggered nicks. The PCR 
product is treated with Dpn I –endonuclease which is used to digest the parental DNA 
template and to select for synthesized mutated DNA. It is relevant to use plasmid DNA 
isolated from a dam+ E.coli strain. Dam (DNA adenine methylase) is an enzyme which 
helps the cell to separate the template strand and newly synthesized strand by adding a 
methyl group to the adenine in newly synthesized DNA. Secondly, the XL1-Blue 
supercompetent cells (E.coli) are transformed with the nicked vector DNA containing 
the mutations. After transformation the supercompetent cells repair the nicks in the 
mutated plasmid (Figure 9, p.25). (Stratagene, 2005)
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
FIGURE 9. Site-directed mutagenesis. The mutation is generated with PCR. The plasmid is 
denatured and the primers containing the desired mutation are annealed into the plasmid. Dpn I 
is used in digestion. XL1-Blue supercompetent cells are transformed with the mutated plasmid. 
(Modified; Stratagene, 2005)









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2.6.3 Protein production in baculovirus system 

Baculoviruses are rod-shaped viruses and contain a large circular dsDNA genome. 
These pathogen viruses infect insect cells or insect larvae. Baculoviruses are safe to 
work with since they are not infectious to vertebrates(Invitrogen, instruction manual, 
2010) They are divided into two generas, Granulovirus genus (GV) and 
Nucleopolyhedrovirus (NPV) (Sherwood L.M. et al., 2009)

A baculovirus particle contains viral DNA surrounded by a cylindrical nucleocapsid. 
The particles are often located in an occlusion body called polyhedron inside the 
nucleus of an infected cell.(Glick B.R. et al., 2010) Polyhedron is mainly made up of a 
protein called polyhedrin which protects the virus from the outside environment such as 
heat, low pH or chemicals (Sherwood L.M. et al., 2009)After the infected insect dies, 
large amount of polyhedron is released and migrated to the midgut of the insect where 
an alkaline environment forces the polyhedrin protein coat to dissolve. This induces the 
infected nucleocapsids to release and migrate to the nucleus where the nucleocapsid is 
removed. (Glick B.R. et al., 2010)

The viral replication occurs in the nucleus of the midgut cells whereof the infection can 
spread from cell to cell through the cell membrane (Sherwood L.M. et al., 2009)This 
form of the virus is called a budding form including a single nucleocapsid. While the 
virus particles become separated from the insect cell, the infected cell membrane 
envelopes the nucleocapsid. The insect dies during one week after the infection and as a 
result, a quarter of the dry weight of the insect consists of polyhedron. (Glick B.R. et al., 
2010)
Baculovirus system can be utilized in the production of heterologous proteins. One 
example of such system is a commercial Bac-to-Bac® Baculovirus expression system 
(Invitrogen) where the insect cells are transfected with the recombinant bacmid DNA. 






27 
2.6.4 Overview of Bac-to-Bac® Baculovirus expression system 

Bac-to-Bac® Baculovirus Expression System (Invitrogen) is an efficient method to 
produce high levels (up to 1000 mg/mL), post-translationally modified, biologically 
active and functional recombinant proteinsThe reason why Baculovirus Expression 
Vector System (BEVS) has been widely used is its ability to express high levels of 
heterologous genes especially for intracellular proteins. The produced recombinant 
proteins are often soluble and are easily collected from infected cells in the late phase of 
infectionBaculovirus system are also faster and cheaper to use than other mammalian 
cell system. (Invitrogen, instruction manual, 2010)

The BEVs utilizes Autographa californica nucleopolyhedrosis virus (AcNPV), a 
subgroup of NPV, which often propagates in cell lines derived from the fall armyworm, 
Spodoptera frugiperda. This subgroup of Nucleopolyhedrovirus has a polyhedrin 
promoter. (Invitrogen, instruction manual, 2010) The polyhedron promoter is very 
strong and therefore polyhedrin genes are highly expressed. Replacement of these genes 
with foreign genes will promote the baculovirus to express recombinant proteins (Figure 
10, p. 28). (Invitrogen, instruction manual, 2010)

pFastBac1 is a donor vector containing the gene of interest, two selection genes, Amp
r
 
and Gen
r
, two flanking sites (Tn7R and Tn7L) and a polyhedron promoter. The vector is 
transformed into supercompetent DH10Bac cells which contain bacmid DNA with a 
mini-attTn7 target site and helper plasmid. The cells are engineered to contain viral 
genome and after transformation the gene of interest in incorporated into the viral 
genome and becomes a part of the viral genome. Flanking sites allow the recombination 
of the bacmid DNA and the gene of interest, and the helper plasmid provides proteins 
for the transposition. The recombinant bacmid DNA is selected using blue-white 
selection. The mini-attTn7 target site on the bacmid is attached by the Tn7 insertions, 
leading the expression of lacZα peptide to disrupt As a result, the recombinant bacmid 
will appear as white colonies, while blue colonies contain only the vector. (Invitrogen, 
instruction manual, 2010)
 
The recombinant bacmid DNA is isolated and purified from a small-scale E.coli culture 
and Sf9 insect cells are transfected with the recombinant bacmid DNA. After 
transfection, the viable virus begins budding into the media. The viral particles are 
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harvested from the media and then used to infect fresh insect cells. The insect cells 
express the desired protein which can be purified and analyzed. (Invitrogen, instruction 
manual, 2010)
 

FIGURE 10. Production of mutant recombinant protein with Bac-to-Bac® Expression System 
using pFastBac™1 donor vector (Invitrogen). 1) The gene of interest is first cloned into the 
pFastBac™1 donor vector 2) Transformation of the competent DH10Bac™ E.coli cells which 
contain the bacmid with a mini-attTn7 target site and the helper plasmid 3)The pFastBac™1 
donor vector exists after the mini-Tn7 element on the plasmid has transposed to the mini-attTn7 
target site on bacmid 4) The absence of the recombinant bacmid is identified with blue-white 
selection 5) The recombinant bacmid DNA is isolated from selected E.coli colonies 6)Viral 
replication of the recombinant baculovirus particles 7) The insect cells are cultured and 
transfected with the recombinant bacmid DNA and as a result, the insect cells will produce 
mutant recombinant protein. (Modified; Invitrogen, instruction manual, 2010)
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 AIM OF THE STUDY 3
 
The objective of the study is to investigate the solubility, structure and function of JH1-
JH2 domains of JAK2 recombinant protein. Following phosphorylation, the both 
domains become catalytically active and therefore producing inactive protein 
components have shown to be challenging. By mutating the K581A in the JH2 domain, 
the protein would have a catalytically inactive JH2 domain. This can be used in 
analysing to the autophosphorylation of JH1-JH2 proteins and the phosphorylation of 
other substrates. 
 
The purpose of the thesis is to produce soluble protein product that consists of mutated 
JH1-JH2 domains of JAK2. The JH1 domain contains a D976N mutation and an 
additional K581A mutation will be introduced into the JH2 domain. The D976N 
mutation inhibits the hydrolyzation of ATP and kills kinase activity in JH1 without 
interfering with the binding of ATP. The mutated DNA construct will be transformed 
into DH10Bac cells for generating bacmid DNA, which will be isolated and analysed by 
agarose gel electrophoresis and PCR. Insect cells will be transfected with the 
recombinant bacmid DNA to produce mutant proteins which will further be purified and 
analysed. 
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 MATERIALS AND METHODS 4
 
 
4.1. Generating K581A mutation into JH1-JH2 domains of JAK2 protein 
 
 
4.1.1 JAK2 constructs 
 
The JAK2 JH1-JH2 constructs (Figure 11) were cloned into the pFastBac™1 
(Invitrogen) donor vector (Figure 12, p.32). JAK2 gene constructs contained D976N 
mutation in JH1-JH2 domains but additional K581A mutations were generated with 
QuickChange® Site-Directed Mutagenesis Kit (Stratagene). The pseudokinase domain, 
JH2 was mutated into two different JAK2 contructs, aa536-1132 and aa513-1132.


FIGURE 11 Schematic presentation of the JAK2 constructs; JH2 is pseudokinase domain and 
JH1 is kinase domain which contained D976N mutation. K581A mutations were generated into 
wild types aa536-1132 and aa513-1132.

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
FIGURE 12. pFastBac™1 vector (Invitrogen). The K581A mutations were cloned into the 
pFastBac™1 donor vector. pFastBac™1 contains the origin of replication (ORI), two selection 
genes, Amp
r
 and Gen
r
, two flanking sites (Tn7R and Tn7L), restriction site for several 
restriction endonucleases and a polyhedron promoter.
 
 
4.1.2 Mutagenesis 
 
Mutagenesis was performed with the reagents presented in table 2 and the PCR program 
used in PCR is shown in table 3 Purified primers used for generating the K581A 
mutation are shown in table 1. In this particular mutation nucleotides encoding lysine 
(AAA) were converted to nucleotides encoding alanine (GCA). Samples were prepared 
on ice and PfuTurbo DNA polymerase was added last.
 
 
TABLE 1. Primers for generating K581A mutation in JH1-JH2 JAK2 protein 
F 5’- ACA GAA GTT CTT TTA GCA GTT CTG GAT AAA GCA -3’ 
R 5’- TGC TTT ATC CAG AAC TGC TAA AAG AAC TTC TGT -3’ 
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TABLE 2 Reagents for mutagenesis
Reagent Amount (one sample) 
10 x Reaction Mix 5 µl 
Template DNA 1 µl 
Primer (forward) 1 µl 
Primer (reverse) 1 µl 
dNTP Mix 1 µl 
Sterile Water 41 µl 
Total 50 µl 
PfuTurbo DNA polymerase 1 µl 

 
TABLE 3. PCR program for mutagenesis
Step Temperature Time  
1 95 °C 30 s  
2 95 °C 30 s 
 
3 55 °C 1 min 
4 68 °C 6,5 min 
5 68 °C 5 min  
 
 
4.1.3 Sequencing 
 
The sequences of mutated JAK2 constructs were analyzed and the nucleotide sequence 
of both JAK2 constructs were compared to mRNA of JAK2. The reagents for 
sequencing are shown in table 4. Each PCR product (2 µl) was prepared for sequencing 
using optimized instructions (Koskenalho E., 2011). Master mix was added into the 
PCR tubes on ice and run by a program shown in table 5 The DNAs were precipitated 
by adding sodium acetate and absolute ethanol after which the tubes were incubated at 
room temperature and centrifuged for 20 minutes. Supernatants from both tubes were 
discarded and 70 % ethanol was added into the PCR tubes. The tubes were dried and 
Hi-Di™ formamide was addedThe actual sequences were resolved using genetic 
analyzer at separated sequencing core laboratory at the University of Tampere, IBT.
16 cycles 
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TABLE 4. Reagents for sequencing 
Step Reagent Amount (one sample) 
PCR 3,3 pmol of Primer 1 µl 
Sequencing buffer 1 µl 
Big Dye 1 µl 
H2O 5 µl 
Total 8 µl 
Precipitation Sodium acetate 1 µl 
100 % Ethanol 22 µl 
70 % Ethanol 200 µl 
Resuspension Hi-Di™ Formamide 15 µl 


TABLE 5. PCR program for preparing the mutated DNA samples for sequencing. 
Step Temperature Time  
1 96 °C 1 min  
2 96 °C 10 s  
3 50 °C 10 s 
4 60 °C 4 min 
5 60 °C 10 min  
6 4 °C cooling/stop  

 
4.1.4 Transformation 
 
After generating the mutations, the circular and nicked dsDNA was transformed into 
XL1-Blue supercompetent cells which repair the nicks in the mutated plasmid. From 
both mutated gene constructs 1 µl of the Dpn I-treated PCR product was added into the 
supercompetent cells on ice. The samples were kept on ice for 30 minutes and treated 
with a heat shock at 42 °C for 45 seconds. The reagents (Agilent Technologies) for 
transformation are presented in table 6
33 cycles 
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TABLE 6: Reagents for transforming the XL1-Blue supercompetent cells
Reagent Amount (one sample)
Dpn I endonuclease 1 µl
XL1-Blue supercompetent cells 50 µl 
PCR-product 1 µl 
NZY broth -medium 500 µl 
LB-agar plates + ampicillin 1 plate


Each transformation reaction was incubated in preheated NZY broth -medium on a 
shaker at 37 °C for one hour. 250 µl of the transformation mixture was spread on LB-
agar plates containing ampicillin and incubated at 37 °C overnight to obtain 
recombinant E.coli cultures. Five colonies from both plates were selected and used for 
plasmid DNA extraction and for the plasmid DNA concentration measurement

 
4.1.5 Isolation of plasmid DNA 
 
The plasmid DNA was extracted from recombinant E.coli cultures by using GenElute™ 
HP Plasmid Miniprep Kit (Sigma). The reagents provided by the kit are presented in 
table 7. Harvested bacterial cells were resuspended into resuspension solution 
containing RNAse. The cells were lysed with lysis buffer. The cell debris was 
precipitated by adding neutralization buffer and centrifuging at 16,000 g

Possible contaminants were removed using column preparation buffer and the cells 
were washed by wash solution 1 and 2. The purified plasmid DNA was eluted by 
transferring the column into a fresh eppendorf-tube and adding TE into the column. The 
column was erased and DNA concentration measured. 

35 
TABLE 7: Reagents for plasmid DNA isolation 
Reagent Amount for one sample 
Resuspension solution (RNAse added) 200 µl
Lysis buffer 200 µl
Neutralization buffer 350 µl
Column preparation buffer 500 µl
Wash solution 1 500 µl
Wash solution 2 (diluted with ethanol) 750 µl
Tris-EDTA buffer 50 µl 


4.2. Preparation and isolation of recombinant bacmid 
 
 
4.2.1 Transforming DH10Bac E.coli 
 
Reagents for transformation of DH10Bac -cells are presented in table 8. The DH10Bac -
cells and the purified plasmid DNA were mixed together in an eppendorftube. They 
were incubated on ice for 30 minutes, treated with a heat shock at 42 °C for 45 seconds 
and transferred back on the ice for 2 minutes. The samples were incubated in S.O.C -
media on a shaker at 37 °C for 6 hours. IPTG and X-Gal were added on the bacmid-
plates to achieve blue-white selection. 50 µl of the incubated mixture was spread on the 
bacmid-plate containing antibiotics, IPTG and X-Gal. The plates were incubated at 37 
°C for 2 days to achieve the blue and white colonies










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
TABLE 8: Reagents for transforming DH10Bac E.coli 
Reagents Concentration Amount 
DH10Bac competent cells 109/ml 100 µl 
Isolated plasmid DNA (measured) 1 µl 
Bacmidplates LB-agar 500 ml 
Kanamycin 50 µg/ml 1 ml 
Gentamycin 7 µg/ml 0,5 ml 
Tetracycline 10 µg/ml 0,5 ml 
Blue-white selection IPTG 100 mM 25 µl (one plate)
X-Gal 20 mg/ml 25 µl (one plate)


S.O.C media 
2 % Tryptone 

900 µl 
0,5 % Yeast Extract 
10 mM NaCl 
2,5 mM KCl 
10 mM MgCl2
10 mM MgSO4
20 mM Glucose 

 
4.2.2 Isolation of recombinant bacmid DNA 
 
Two positive colonies were selected for restreaking to ensure they are truly white. 
Restreaking was done by spreading two white, large and separated colonies on a fresh 
bacmid-plate containing X-Gal and IPTG (table 8). The plates were incubated at 37 °C 
over night. 

A single colony was selected from the plate to produce a liquid E.coli culture containing 
the antibiotics shown in table 8. Reagents for recombinant bacmid DNA isolation are 
presented in table 9. Bacterial suspension (3 ml) was transferred into an eppendorf-tube 
and centrifuged at 8,000 rpm for 3 minutes. Supernatant was discarded and pellet was 
resuspended with Sol I containing RNAse A to degrade RNA. Sol II was added to the 
tubes and they were inverted six times. The tubes were placed in room temperature for 2 
minutes and lids open 30 seconds. Sol III was added and the tubes were inverted 8 times 
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and placed on ice for 10 minutes. The tubes were centrifuged at 16,000 g for 20 
minutes. 

The supernatant was inserted to a new tube containing isopropanol and placed on ice for 
10 minutes inverting them a few times for precipitation. The tubes were centrifuged at 
16,000 g and the supernatants were carefully discarded. Small pellets were washed with 
ethanol and centrifuged at 16,000 g for 5 minutes. The supernatants were removed in 
sterile environment. The pellets were air dried lids open for 10 minutes after which the 
DNA was dissolved in TE for 30 minutes.  

TABLE 9: Reagents for isolation of recombinant bacmid DNA 
Reagents Contents Amount for one sample

Sol I + RNAse A 
50 mM Glucose 300 µl of Sol I +  9 µl of 
RNAse A 25 mM Tris-HCl pH 8 
10 mM EDTA  pH 8 

Sol II 
0,2 M NaOH 300 µl 
1 % SDS 
 
Sol III 
3 M K-Acetate 300 µl 
Acetic Acid 
Isopropanol  800 µl
70 % EtOH  500 µl
TE

10 mM Tris-HCl pH 8 40 µl 
1 mM EDTA pH 8 

 
4.2.3 Analysis of recombinant bacmid DNA 
 
The bacmid DNAs were analyzed by agarose gel electrophoresis to confirm the 
presence of high molecular weight DNA. PCR analysis was done to verify successful 
transposition to the bacmid. The reagents for agarose gel electrophoresis are presented 
in table 10. The agarose gel (0.5 %) was prepared using 1x TAE-buffer and 1 kb DNA 
as a marker. The gel was run at 80 V with 400 mA. A thicker 0.7 % gel was prepared 
for agarose gel electrophoresis after the PCR analysis which was run by a program 
shown in table 13. The reagents for PCR analysis are presented in table 11, the primers 
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are shown in table 12, and the reagents used for the thicker gel are shown in table 
14The gel was run at 80 V with 400 mA. 

TABLE 10: Reagents for agarose gel electrophoresis 
 Reagents Amounts

0,5 % gel 
Agarose 0,2 g 
1x TAE 40 ml 
EtBr 16 mg/ml 10 µg

Samples 
10x loading buffer 2 µl 
Sterile water 12 µl 
Bacmid DNA 6 µl 
Marker (GeneRuler) 1 kb DNA 5 µl 


TABLE 11: Reagents for PCR analysis of recombinant bacmid DNA 
Reagents Amount (one sample)
10x PCR Buffer (contains MgCl2) 5 µl 
dNTP mix 10 mM 1 µl 
Primer I 10 µM 1,25 µl 
Primer II 1,25 µl 
Template DNA 1 µl
Taq polymerase 2,5 U 0,5 µl
Sterile water 40 µl

 
TABLE 12. M13/pUC Amplification primers for the analysis of recombinant bacmid DNA 
F 5’- GGT TTT CCC AGT CAC GAC  -3’ 
R 5’- AGC GGA TAA CAA TTT CAC AC -3’ 




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TABLE 13. PCR -program for bacmid DNA analysis



TABLE14: Reagents for agarose gel electrophoresis for bacmid DNA transposition
 Reagents Amounts

0,7 % gel 
Agarose 0,28 g
1x TAE 40 ml 
EtBr 0,16 mg/ml 10 µg

Samples 
10x loading buffer 2 µl 
PCR product 18 µl 
Marker (GeneRuler) 1 kb DNA 5 µl 



4.3. Recombinant protein production in Sf9 insect cells 
 
4.3.1 Transfection 
 
The Sf9 (Spodoptera frugiperda) insect cells (Invitrogen) were transfected for 
generating P0. P1 virus is the virus harvested after infecting the insect cells with P0 
virus. The cells were first cultured in Grace’s Insect Medium free from any antibiotics 
or serumThe cell density was 1x16/ml and viability over 95 %. The insect cells were 
allowed to attach for 15 minutes at room temperature after which they were transfected 
with baculovirus DNA in a 6-well plate. A-and B-solutions were prepared using the 
reagents shown in table 15. The solutions were combined (transfection mixture) and 
incubated at room temperature for 20 minutes. The mixed solution was added onto the 
cells and incubated at 27 °C for 5 hours. The transfection mixture was discarded and 
replaced with a fresh Grace’s Insect Medium containing 10 % FBS The cells were 
Temperature Time 
94 °C 5 min 
94 °C 45 s 
55 °C 45 s 
72 °C 5 min 
94 °C 45 s 
31 cycles 
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incubated at 27 °C for 72 hours to obtain viral infection in the cells to obtain the P0 -
virus.100 µl of the P0 stage of infected virus was cultured in 10 ml petri dish to obtain 
theP1 -virus. Both viral stages (P0 and P1) were analyzed with Western blot.

TABLE 15. The Reagents for culturing insect cells and transfecting the cells with baculovirus 
DNA
Step Reagent Amount 
Culturing the Sf9 
cells 
Sf9 insect cells  
Grace’s Insect Medium, containing 
10 % FBS (Fetal Bovine Serum)
2 ml (one well) 
Transfection 
A 
Cellfectin® II 8 µl 
Grace’s Medium 100 µl 
B 
Purified Bacmid DNA 1 µg 
Grace’s Insect Medium 100 µl 
Grace’s Insect Medium, containing 
10 % FBS
2 ml (one well)


4.3.2 Cell lysis, SDS-PAGE and Western Blot 
 
The transfected cells and control cells were lysed on ice with 200 µl of lysis buffer 
shown in table 16. The cells were scrapped and left on ice for 15 minutes after which 
they were centrifuged at 4 °C for 15 minutes. Proteins were separated by SDS-PAGE 
(sodium dodecyl sulphate polyacrylamide gel electrophoresis) with reagents shown in 
table 15. Each lysate (15 µl) was mixed with 5 µl of 4x SDS and loaded onto 10 % gel 
The non-infected cells were used as a control sampleThe gels were run at 180 V with 
400 mA for 45 minutes and transferred onto a nitrocellulose membranes (Whatman® 
PROTRAN®) using a Trans-blot® SD semi-dry transfer cell apparatus (BIO-RAD).  

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TABLE16: Reagents for cell lysis
Reagents Contents Amounts 
Lysis Buffer
1 % Triton X-100 5 ml 
Sodium vanadate 100 µl 
Proteinase (approtinin) 40 µl 
PMSF (phenylmethylsulphonyl fluoride) 50 µl 
 

The reagents used in the blotting are shown in table 17. Each membrane was blocked in 
5 % BSA for 1 hour at room temperature on a shaker to prevent the unspecific binding 
of the antibody. The membranes were incubated in the specific primary antibody on a 
shaker at 4 °C overnight, after which the membranes where washed 10 minutes with 
each (0,05-0,5 %) Tween TBS washing buffers. Both membranes were incubated in the 
secondary antibody for 1 hour on a shaker to achieve binding between the primary and 
secondary antibodies. The membranes were visualized using autoradiography (BioMax 
MR film, Kodak).

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TABLE 17: Reagents for SDS-PAGE and Western blot
Step Reagents Contents 
Gel run 
Running Buffer 
25 mM Tris 
192 mM Glycine 
1 % SDS 
4x SDS (Sodium Dodecyl 
Sulphate) 
10 ml Glycerol 
5 ml Tris pH 6,8 
5 ml 2-mercaptoethanol 
10 mg Bromophenol blue 
3 g SDS 
Marker
PageRuler™ Plus Prestained protein 
ladder (Fermentas)
Transfer Transfer Buffer 
30,8 mM Tris 
0,24 mM Glycine 
20 % methanol 
Blocking Blocking Buffer 
0,05 % Tween TBS 
5 % BSA (bovine serum albumin) 
Antibodies 
Primary AB αJAK2rabbit1:1000 (Upstate Biotech)
Secondary AB 
anti-rabbit lgG-HRP (Santa Cruz 
Biotech) + 0,05 % Tween TBS 1:15 
000
Washing Tween + 1x TBS 
0,05 % Tween TBS 
0,1 % Tween TBS 
0,5 % Tween TBS 
Detection 
Detection reagent 1. luminol substrate
Detection reagent 2. peroxide solution

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5.1. Mutagenesis and plasmid DNA analysis 
 
After generating the mutants in both, aa513-1132 and aa536-1132 residues, the 
constructs were sequenced to confirm the successful mutagenesis of K581A. The 
mutations were generated into pFastBac™1 plasmid vector (Invitrogen). Nucleotide 
sequence of both JAK2 constructs was compared to mRNA of JAK2. Sequencing 
results showed that the mutation K581A was achieved in the pseudokinase domain 
(JH2). XL1-Blue supercompetent cells were transformed with the particular mutated 
pFasctBac1 vector and grown in a small scale E.coli culture.  Plasmid DNA 
concentration and purity were measured to verify the quality of the desired plasmids. 
Five colonies from both recombinant E.coli cultures were measured (table 18) Samples 
3 and 10 were selected for plasmid DNA isolation 

TABLE 18: Concentration and purity of the isolated plasmid DNA 
 aa513 – aa1132 aa536 – aa1132 
 1 2 3 4 5 6 7 8 9 10
Conc. 
ng/µl 
187,8 264,9 60,0 247,8 224,9 160,2 273,0 260,5 - 269,1 
Purity 1,88 1,90 1,94 1,88 1,86 1,91 1,87 1,87 - 1,89 

 
5.2. Verifying the quality of bacmid DNA 
 
The mutated pFastBac™1 vectors were transformed into the DH10Bac cells. 
Recombinant DNAs were selected by blue-white selection. Two white positive colonies 
from both constructs were selected for restreaking whereof a single colony was selected 
for the production of liquid E.coli cultures. The recombinant bacmid DNAs were 
isolated from both cultures. 
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The bacmid DNAs were analyzed by agarose gel electrophoresis to confirm the 
presence of high molecular weight DNA. Bacmids are large molecules and therefore 
they migrate slowly on the gel (Figure 13). Bands 1-2 present the wild types aa536-
1132 and bands 3-4 the wild types aa513-1132. Band three shows that the bacmid DNA 
purification was not achieved in one of the aa513-1132 wild type in contrast with the 
wild type aa536-1132. 
  
1 2 3 4 M 
 

FIGURE 13. Purified bacmid DNA run by agarose gel electrophoresis.  
Bands 1-2 present the wild types aa536-aa1132 and bands 3-4 the wild types aa513-aa1132
 
The PCR analysis was performed to confirm that the gene of interest has transposed to 
the bacmid. When the gene of interest has transposed with pFastBac
™
1, the amplified 
size is 2300 bp plus the size of insert (843 bp). Bands 1-2 (Figure 14) present the wild 
types aa536-aa1132 and bands 3-4 the wild types aa513-aa1132. All samples migrated 
on the gel near the size of 3143 bp which indicates successful transposition. 

1 2 3 4 M 
 
FIGURE 14. Agarose gel electrophoresis was performed
to confirm the transposition of the desired gene to the bacmid.  
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5.3. Validation of high protein expression 
 
The Western blot results (Figure 15) confirm the high protein expression of the 
recombinant JAK2 proteins in Sf9 cellsThe left figure (15a.) shows the protein 
expression at P0 stage as done by using anti-JAK2 antibody. The molecular weight of 
JAK is approximately 130 kDa and the JH1-JH2 domains comprise half of the whole 
molecule which is 65 kDa (Figure 15a.b). The aa513-1132 is a larger construct than 
aa536-1132, and therefore the it migrates more slowly on the gel (Figure 15a.). The 
right panel (15b.) presents the expression at P1 stage infection, which shows a very 
robust expression for aa513-1132 construct


  


FIGURE 15High protein expression of recombinant JH1-JH2 of JAK2 in Sf9 cells 
a) P0 stage virus infection and protein expression  
b) P1 stage virus infection and protein expression

 
On the contrary, aa536-1132 construct shows weak bands due to its insolubility. The 
insolubility of a protein can be found during the infection stages P1-P2 when the viral 
amplification occurs. The construct aa513-aa1132 is soluble (Figure 15b.) appearing 
with the clear bands. This construct was used in protein production stage P3, but also 
revealed to be insoluble. 

 
70 kDa 
50 kDa 
a. b. 
70 kDa 
50 kDa 
513
3 
536 536 513 
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The purpose of this study was to generate K581A kinase-inactivating point mutation 
into JH1-JH2 domains of JAK2 protein and produce mutant JAK2 in baculovirus 
system. The objective of the study was to analyze the solubility and biological function 
of recombinant JAK2 protein. Two different sizes of constructs were mutated and 
transformed into competent DH10Bac cells containing bacmid DNA. Recombinant 
bacmid DNA was isolated and introduced to Sf9 (insect) cells which expressed the 
desired proteins.   
 
Producing soluble protein components have been shown to be a difficult task when it 
comes to protein kinases which are highly phosphorylated, leading them to become 
unstable in vitro. In contrast, many kinases cannot be produced as unphosphorylated 
proteins, obviously due to highly hydrophobic residues on their surface that interfere 
with their solubility. Stabilizing the structure of JAKs is required to obtain a stable and 
soluble protein. The previous structural studies of JH1 domain of JAKs were achieved 
only after the JH1 domain was coupled with a specific inhibitor or compound. 
 
The results indicate that the used baculoviruses were able to encode recombinant JH1-
JH2 JAK2 protein with residues 536-1132 and 513-1132. The results also show that the 
Sf9 (insect) -cells were able to express the recombinant JAK2 protein but not in soluble 
form, referring that the objective of the thesis was not achieved.

The domains JH1 and JH2 are both catalytically active domains which complicates the 
biological and structural studies of the protein. Before this thesis project began, a 
mutation D976N was introduced in the JH1 domain. D976N mutation kills the ATP-
binding activity of JH1 domain but does not harm the protein structure. This mutant 
protein JH1-JH2 D976N was shown to be highly soluble in Sf9 -cells, but at same time 
it was structurally highly unstable. During this thesis, another mutation K581A was 
generated in the JH2 domain. The K581A mutation removes the ATP-binding activity 
of JH2 domain but also keeps the domain structure unharmed. When this protein with 
two different mutations was produced in Sf9 cells, the protein was insoluble referring 
that the two mutations (K581A and D976N) together, could interfere with the stability 
of the protein.  
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This study was a part of a wider ongoing research, and more mutation studies where a 
stable two-domain structure for JAK2 kinase is produced, are required. Especially, the 
JH2 domain as a regulator of the whole JAK2 protein is essential for the function of 
JAK2. The recent studies show that JH2 domain phosphorylates negatively in two sites, 
Ser523 and Tyr570 which are conserved only in JAK2. Previous structural studies also 
show that for example MPN mutation V617F impairs the catalytic activity of the JH2 
domain. As a result, JAK2 loses its negative regulatory mechanism and the JH2 domain 
becomes constitutively activated.  
 
Several inhibitors as therapeutical drugs for JAK2 have been tested but the results have 
not been satisfying. Producing JAK2 mutation specific inhibitors is the most desirable 
solution for drug development, and structural information obtained from 
crystallographic data on soluble proteins is essential for drug development. Therefore 
constructing soluble recombinant proteins and being able to harvest them is of interest 
for researchers.  
 
The mutations were generated using the QuikChange® site-directed mutagenesis and 
the Bac-to-bac® Baculovirus Expression System was used to produce desired 
recombinant proteins. Both assays included several smaller steps such as DNA 
isolation, transformation, sequencing, transfection, blue-white selection, agarose gel 
electrophoresis, PCR analysis and Western blotting. In this thesis, the different steps 
were repeated if necessary but the methods were entirely used only once. Only the 
crystal structures of pseudokinase (JH2) and kinase (JH1) domain have been resolved. 
More recombinant protein production is required for X-ray crystallography studies 
which will give more information on the three-dimensional structure and catalytic 
activity of JAK2 and allow the development of new therapeutic drugs for a trial.  
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